Heterologous_JJ Human_NP Immunodeficiency_NN Virus_NP Type_NP 1_CD Lentiviral_NP Vectors_NP Packaging_NP a_DT Simian_NP Immunodeficiency_NN Virus-Derived_NP Genome_NP Display_NP a_DT Specific_NP Postentry_NP Transduction_NP Defect_NN in_IN Dendritic_NP Cells_NP Heterologous_NP lentiviral_JJ vectors_NNS (_( LVs_NP )_) represent_VBP a_DT way_NN to_TO address_VB safety_NN concerns_NNS in_IN the_DT field_NN of_IN gene_NN therapy_NN by_IN decreasing_VBG the_DT possibility_NN of_IN genetic_JJ recombination_NN between_IN vector_NN and_CC packaging_NN constructs_NNS and_CC the_DT generation_NN of_IN replication-competent_JJ viruses_NNS ._SENT Using_VBG described_VBN LVs_NP based_VBN on_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) and_CC simian_JJ immunodeficiency_NN virus_NN MAC251_NP (_( SIVMAC251_NP )_) ,_, we_PP asked_VBD whether_IN heterologous_JJ virion_NN particles_NNS in_IN which_WDT trans-acting_NN factors_NNS belonged_VBD to_TO HIV-1_NP and_CC cis_NNS elements_NNS belonged_VBD to_TO SIVMAC251_NP (_( HIV-siv_NP )_) would_MD behave_VB as_IN parental_JJ homologous_JJ vectors_NNS in_IN all_DT cell_NN types_NNS ._SENT To_TO our_PP$ surprise_NN ,_, we_PP found_VBD that_IN although_IN the_DT heterologous_JJ HIV-siv_NP vector_NN was_VBD as_RB infectious_JJ as_IN its_PP$ homologous_JJ counterpart_NN in_IN most_JJS human_JJ cells_NNS ,_, it_PP was_VBD defective_JJ in_IN the_DT transduction_NN of_IN dendritic_JJ cells_NNS (_( DCs_NP )_) and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, macrophages_NNS ._SENT In_IN DCs_NP ,_, the_DT main_JJ postentry_NN defect_NN was_VBD observed_VBN in_IN the_DT formation_NN of_IN two-long-terminal-repeat_JJ circles_NNS ,_, despite_IN the_DT fact_NN that_IN full-length_JJ proviral_JJ DNA_NN was_VBD being_VBG synthesized_VBN and_CC was_VBD associated_VBN with_IN the_DT nucleus_NN ._SENT Taken_VBN together_RB ,_, our_PP$ data_NNS suggest_VBP that_IN heterologous_JJ HIV-siv_NP vectors_NNS display_VBP a_DT cell-dependent_JJ infectivity_NN defect_NN ,_, most_RBS probably_RB at_IN a_DT post-nuclear_JJ entry_NN migration_NN step_NN ._SENT As_IN homologous_JJ HIV_NP and_CC SIV_NP vectors_NNS do_VBP transduce_VB DCs_NP ,_, we_PP believe_VBP that_IN these_DT results_NNS underscore_VBP the_DT importance_NN of_IN a_DT conserved_VBN interaction_NN between_IN cis_NN elements_NNS and_CC trans-acting_VBG viral_JJ factors_NNS that_WDT is_VBZ lost_VBN or_CC suboptimal_JJ in_IN heterologous_JJ vectors_NNS and_CC essential_JJ only_RB in_IN the_DT transduction_NN of_IN certain_JJ cell_NN types_NNS ._SENT For_IN gene_NN therapy_NN purposes_NNS ,_, these_DT findings_NNS indicate_VBP that_IN the_DT cellular_JJ tropism_NN of_IN LVs_NP can_MD be_VB modulated_VBN not_RB only_RB through_IN the_DT use_NN of_IN distinct_JJ envelope_NN proteins_NNS or_CC tissue-specific_JJ promoters_NNS but_CC also_RB through_IN the_DT specific_JJ combinatorial_JJ use_NN of_IN packaging_NN and_CC transfer_VB vector_NN constructs_NNS ._SENT Lentiviral_JJ vectors_NNS (_( LVs_NP )_) are_VBP useful_JJ tools_NNS for_IN the_DT delivery_NN of_IN genes_NNS with_IN potential_JJ therapeutic_JJ applications_NNS ._SENT The_DT major_JJ advantage_NN of_IN LVs_NP over_IN other_JJ gene_NN delivery_NN systems_NNS lies_VBZ in_IN their_PP$ ability_NN to_TO pass_VB through_IN an_DT intact_JJ nuclear_JJ membrane_NN barrier_NN and_CC to_TO integrate_VB into_IN the_DT host_NN genome_NN ._SENT For_IN gene_NN therapy_NN purposes_NNS ,_, this_DT translates_VBZ into_IN the_DT possibility_NN of_IN integrating_VBG the_DT transgene_NN of_IN interest_NN ,_, ensuring_VBG its_PP$ durable_JJ expression_NN ,_, and_CC the_DT ability_NN to_TO target_VB highly_RB differentiated_VBN cells_NNS ._SENT LVs_NNS have_VBP now_RB been_VBN developed_VBN from_IN primate_NN lentiviruses_NNS ,_, such_JJ as_IN the_DT human_JJ and_CC simian_JJ immunodeficiency_NN viruses_NNS (_( HIV-1_NP ,_, HIV-2_NP ,_, SIVMAC251_NP ,_, and_CC SIV1A11_NP )_) ,_, as_RB well_RB as_IN from_IN nonprimate_JJ lentiviruses_NNS ._SENT Common_JJ to_TO all_DT such_JJ vectors_NNS is_VBZ the_DT physical_JJ separation_NN of_IN functions_NNS normally_RB encoded_VBN by_IN the_DT retroviral_JJ genome_NN into_IN separate_JJ constructs_NNS :_: one_CD or_CC more_JJR packaging_NN constructs_NNS that_WDT encode_VBP the_DT trans-acting_NN factors_NNS required_VBN for_IN particle_NN formation_NN and_CC infectivity_NN and_CC a_DT gene_NN transfer_NN vector_NN ._SENT The_DT latter_NN represents_VBZ essentially_RB a_DT miniviral_NN genome_NN ,_, devoid_JJ of_IN viral_JJ open_JJ reading_NN frames_NNS but_CC bearing_VBG the_DT cis_NN elements_NNS required_VBN for_IN viral_JJ infectivity_NN ._SENT As_IN a_DT consequence_NN ,_, the_DT life_NN cycle_NN of_IN LVs_NP mirrors_VBZ that_IN of_IN lentiviruses_NNS in_IN a_DT single-round_JJ infection_NN but_CC LVs_NP are_VBP themselves_PP nonreplicative_JJ ._SENT A_DT major_JJ concern_NN in_IN the_DT use_NN of_IN primate_NN LVs_NP is_VBZ the_DT pathogenicity_NN of_IN their_PP$ parental_JJ viruses_NNS in_IN humans_NNS ._SENT Although_IN LVs_NP are_VBP nonreplicative_JJ ,_, the_DT possibility_NN exists_VBZ that_IN replication-competent_JJ viruses_NNS will_MD be_VB generated_VBN following_VBG recombination_NN between_IN vector_NN and_CC packaging_NN constructs_NNS during_IN the_DT phases_NNS of_IN vector_NN production_NN ._SENT It_PP is_VBZ clear_JJ that_IN the_DT possibility_NN of_IN such_PDT an_DT event_NN ,_, although_IN small_JJ ,_, may_MD temper_VB enthusiasm_NN over_IN the_DT use_NN of_IN LVs_NP in_IN gene_NN therapy_NN ._SENT Theoretically_RB ,_, a_DT possible_JJ strategy_NN to_TO avoid_VB formation_NN of_IN replication-competent_JJ viruses_NNS would_MD be_VB to_TO lower_VB the_DT homology_NN of_IN regions_NNS shared_VBN between_IN the_DT packaging_NN construct_NN and_CC the_DT transfer_NN vector_NN ,_, thus_RB decreasing_VBG the_DT likelihood_NN of_IN recombination_NN ._SENT This_DT may_MD be_VB achieved_VBN ,_, for_IN example_NN ,_, by_IN engineering_NN heterologous_JJ LVs_NP in_IN which_WDT packaging_NN and_CC vector_NN constructs_NNS are_VBP derived_VBN from_IN different_JJ but_CC related_JJ viruses_NNS ._SENT It_PP is_VBZ well_RB documented_VBN that_IN particles_NNS of_IN certain_JJ viruses_NNS can_MD cross_VB package_NN and_CC mobilize_VB the_DT genomic_JJ RNA_NP of_IN a_DT related_JJ virus_NN ,_, giving_VBG rise_NN to_TO heterologous_JJ virion_NN particles_NNS ,_, or_CC RNA_NP pseudotypes_NNS ,_, as_RB in_IN the_DT case_NN of_IN the_DT spleen_NN necrosis_NN virus_NN and_CC more_JJR recently_RB HIV-1_NP ,_, SIV_NP ,_, and_CC the_DT feline_JJ immunodeficiency_NN virus_NN ._SENT Cross_NP packaging_NN is_VBZ the_DT result_NN of_IN a_DT promiscuous_JJ interaction_NN between_IN elements_NNS present_JJ in_IN the_DT different_JJ viral_JJ species_NNS and_CC involved_VBN in_IN viral_JJ RNA_NP packaging_NN in_IN cis_NNS (_( the_DT packaging_NN sequence_NN ,_, PSI_NP )_) and_CC in_IN trans_NNS (_( the_DT nucleocapsid_JJ domain_NN of_IN the_DT Gag_NP polyprotein_NP ,_, NC_NP )_) ._SENT This_DT interaction_NN is_VBZ in_IN most_JJS cases_NNS nonreciprocal_JJ ._SENT Indeed_RB ,_, spleen_NN necrosis_NN virus_NN virion_NN particles_NNS incorporate_VB and_CC mobilize_VB murine_JJ leukemia_NN virus_NN viral_JJ genomic_JJ RNA_NP ,_, while_IN the_DT opposite_NN does_VBZ not_RB occur_VB ._SENT Similarly_RB ,_, HIV-1_NP has_VBZ been_VBN shown_VBN to_TO cross_VB package_NN HIV-2_NP and_CC SIV_NP RNAs_NP ,_, although_IN the_DT reciprocal_JJ situation_NN does_VBZ not_RB occur_VB (_( in_IN the_DT case_NN of_IN HIV-2_NP )_) or_CC occurs_VBZ inefficiently_RB (_( in_IN the_DT cases_NNS of_IN SIV_NP and_CC feline_JJ immunodeficiency_NN virus_NN )_) ._SENT Since_IN HIV-1_NP 's_POS cross_NN packaging_NN of_IN SIV_NP RNA_NP occurs_VBZ efficiently_RB ,_, we_PP used_VBD previously_RB derived_VBN LVs_NP to_TO develop_VB heterologous_JJ LVs_NP in_IN which_WDT trans-acting_NN factors_NNS belonged_VBD to_TO HIV-1_NP and_CC cis_NN elements_NNS in_IN the_DT transfer_NN vector_NN belonged_VBD to_TO SIVMAC251_NP (_( HIV-siv_NP )_) ._SENT Heterologous_JJ HIV-siv_NP LVs_NP have_VBP been_VBN previously_RB engineered_VBN and_CC shown_VBN to_TO be_VB able_JJ to_TO transduce_VB aphidicolin-arrested_JJ cells_NNS ._SENT However_RB ,_, a_DT close_JJ inspection_NN of_IN such_JJ vectors_NNS in_IN comparison_NN with_IN homologous_JJ LVs_NP and_CC in_IN a_DT larger_JJR spectrum_NN of_IN cells_NNS had_VBD not_RB been_VBN carried_VBN out_RP ._SENT This_DT analysis_NN is_VBZ required_VBN if_IN such_JJ vectors_NNS are_VBP to_TO be_VB used_VBN in_IN gene_NN therapy_NN applications_NNS ._SENT In_IN this_DT study_NN ,_, we_PP analyzed_VBD the_DT behavior_NN of_IN heterologous_JJ HIV-siv_NP LVs_NP in_IN close_JJ comparison_NN with_IN that_DT of_IN homologous_JJ LVs_NP in_IN different_JJ human_JJ cell_NN types_NNS ._SENT We_PP show_VBP that_IN despite_IN the_DT fact_NN that_IN the_DT infectivity_NN of_IN heterologous_JJ HIV-siv_NP LVs_NP was_VBD similar_JJ to_TO that_DT of_IN homologous_JJ LVs_NP in_IN most_JJS cells_NNS ,_, they_PP were_VBD ,_, unlike_IN the_DT latter_JJ ,_, incapable_JJ of_IN transducing_VBG differentiated_VBN dendritic_JJ cells_NNS (_( DCs_NP )_) and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, macrophages_NNS ._SENT We_PP characterized_VBD the_DT infectivity_NN defect_NN of_IN HIV-siv_NP vectors_NNS in_IN DCs_NP and_CC were_VBD able_JJ to_TO show_VB that_IN the_DT major_JJ impairment_NN occurs_VBZ in_IN the_DT formation_NN of_IN two-long-terminal-repeat_NN (_( 2LTR_JJ )_) circles_NNS ,_, despite_IN the_DT fact_NN that_DT full-length_JJ (_( FL_NP )_) proviral_JJ DNA_NN was_VBD synthesized_VBN and_CC associated_VBN with_IN the_DT nucleus_NN ._SENT Cells_NNS ._SENT |_SYM The_DT human_JJ monocyte-like_JJ cell_NN line_NN U937_JJ and_CC the_DT human_JJ myeloid_JJ leukemia_NN cell_NN line_NN HL60_NP were_VBD obtained_VBN through_IN the_DT centralized_JJ facility_NN for_IN AIDS_NP reagents_NNS supported_VBN by_IN European_JJ Union_NP program_NN EVA/MRC_NP and_CC the_DT United_NP Kingdom_NP medical_JJ research_NN council_NN ._SENT Primary_JJ lymphocyte_NN and_CC monocyte_NN fractions_NNS were_VBD obtained_VBN from_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS of_IN healthy_JJ donors_NNS at_IN the_DT Etablissement_NP Francais_NP du_FW Sang_NP de_FW Lyon_NP as_RB described_VBD previously_RB ._SENT Briefly_RB ,_, after_IN isolation_NN of_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS by_IN centrifugation_NN in_IN lymphocyte_NN separation_NN medium_NN (_( Eurobio_NP ,_, Les_NP Ulis_NP ,_, France_NP )_) ,_, cells_NNS were_VBD layered_VBN onto_IN a_DT four-step_JJ discontinuous_JJ density_NN gradient_NN (_( 75_CD to_TO 50.5_CD to_TO 40_CD to_TO 30_CD %_NN Percoll_NP at_IN a_DT density_NN of_IN 1.130_CD g/ml_NN ;_: Pharmacia_NP ,_, Uppsala_NP ,_, Sweden_NP )_) to_TO separate_JJ monocytes_NNS from_IN peripheral_JJ blood_NN lymphocytes_NNS (_( PBLs_NP )_) ._SENT After_IN centrifugation_NN at_IN 1,000_CD x_NN g_NN for_IN 25_CD min_NN ,_, monocytes_NNS and_CC lymphocytes_NNS were_VBD recovered_VBN as_IN low-_NN and_CC high-density_NN fractions_NNS ,_, respectively_RB ._SENT Prior_RB to_TO freezing_NN ,_, monocytes_NNS were_VBD further_RBR purified_VBN by_IN negative_JJ selection_NN by_IN using_VBG a_DT cocktail_NN of_IN hapten_NN CD3_NP ,_, CD7_NP ,_, CD19_NP ,_, CD45RA_NP ,_, and_CC CD56_NP anti-immunoglobulin_NP E_NP antibodies_NNS coupled_VBN to_TO MACS_NP microbeads_NNS by_IN following_VBG the_DT manufacturer_NN 's_POS instructions_NNS (_( Miltenyi_NP Biotec_NP ,_, Paris_NP ,_, France_NP )_) ._SENT U937_JJ and_CC HL60_JJ cells_NNS ,_, cells_NNS from_IN the_DT human_JJ T-cell_NN line_NN Jurkat_NP ,_, and_CC PBLs_NP were_VBD cultured_VBN in_IN complete_JJ RPMI_NP 1640_CD medium_NN supplemented_VBN with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN (_( FCS_NN )_) ._SENT Human_NP 293T_NP and_CC HeLa_NP P4P5_NP fibroblasts_NNS (_( HeLa_NP cells_NNS expressing_VBG the_DT CD4_NP and_CC CCR5_NP receptors_NNS and_CC bearing_VBG an_DT HIV-LTR-beta-galactosidase_NN reporter_NN cassette_NN ,_, obtained_VBN from_IN Pierre_NP Charneau_NP ,_, Pasteur_NP Institute_NP ,_, Paris_NP ,_, France_NP )_) were_VBD maintained_VBN in_IN complete_JJ Dulbecco_NP modified_JJ Eagle_NP medium_NN supplemented_VBD with_IN 10_CD %_NN FCS_NN ._SENT For_IN stimulation_NN ,_, PBLs_NP were_VBD treated_VBN for_IN 24_CD h_NN with_IN 1_CD mug_NN of_IN phytohemagglutinin_NN (_( PHA_NP ;_: catalog_NN no_RB ._SENT L8902_NP ;_: Sigma)/ml_NP supplemented_VBD with_IN 150_CD U_NN of_IN human_JJ recombinant_JJ interleukin-2_NN (_( IL-2_NP ;_: catalog_NN no_RB ._SENT 136_LS ;_: obtained_VBN through_IN the_DT National_NP Institutes_NPS of_IN Health_NP [_SYM NIH_NP ]_SYM AIDS_NP reagent_NN and_CC reference_NN program)/ml_NN or_CC with_IN 25_CD ng_NNS of_IN IL-7_JJ (_( R&D_NP Systems)/ml_NP ._SENT DCs_NNS were_VBD differentiated_VBN from_IN monocytes_NNS upon_IN culture_NN for_IN 4_CD to_TO 6_CD days_NNS in_IN granulocyte-macrophage_NN colony-stimulating_NN factor_NN (_( GM-CSF_NP ;_: 100_CD ng/ml_NNS ;_: Schering-Plough_NP )_) and_CC IL-4_NN (_( 100_CD ng/ml_NNS ;_: R&D_NP Systems_NPS )_) in_IN complete_JJ RPMI_NP 1640_CD medium_NN plus_IN 5_CD %_NN FCS_NN or_CC human_JJ AB_NP serum_NN ,_, as_RB described_VBN previously_RB ._SENT At_IN the_DT end_NN of_IN the_DT differentiation_NN period_NN ,_, cells_NNS were_VBD CD14-_NP (_( CD1a+_NP in_IN FCS_NN )_) ,_, had_VBD increased_VBN surface_NN expression_NN of_IN HLA-DR_NP ,_, CD80_NP ,_, and_CC CD86_NP ,_, and_CC upon_IN maturation_NN with_IN lipopolysaccharide_NN ,_, CD40L_NP ,_, or_CC tumor_NN necrosis_NN factor_NN alpha_NN ,_, had_VBD upregulated_JJ CD83_NP ._SENT DCs_NNS differentiated_VBN in_IN this_DT manner_NN were_VBD fully_RB competent_JJ in_IN phagocytosis_NN of_IN latex_NN beads_NNS and_CC in_IN the_DT mixed_JJ lymphocyte_NN reaction_NN ._SENT Macrophages_NNS were_VBD obtained_VBN from_IN purified_VBN monocytes_NNS ._SENT Briefly_RB ,_, monocytes_NNS were_VBD washed_VBN and_CC plated_VBN at_IN 106/ml/well_NP of_IN a_DT 6-well_JJ plate_NN in_IN complete_JJ RPMI_NP 1640_CD medium_NN in_IN the_DT absence_NN of_IN serum_NN for_IN 3_CD h_NN at_IN 37C_JJ ._SENT By_IN this_DT time_NN the_DT majority_NN of_IN monocytes_NNS had_VBD adhered_VBN to_TO the_DT plate_NN ,_, and_CC FCS_NN and_CC GM-CSF_NP were_VBD added_VBN at_IN final_JJ concentrations_NNS of_IN 10_CD %_NN and_CC 100_CD ng/ml_NNS ,_, respectively_RB ._SENT Macrophages_NNS were_VBD cultured_VBN for_IN 6_CD or_CC 17_CD days_NNS under_IN these_DT conditions_NNS ._SENT LV_NP DNA_NP constructions_NNS ._SENT |_SYM The_DT HIV-1-_NP and_CC SIVMAC251-based_NP LV_NP systems_NNS have_VBP been_VBN described_VBN elsewhere_RB (_( in_IN references_NNS and_CC and_CC in_IN reference_NN ,_, respectively_RB )_) ._SENT The_DT packaging_NN constructs_NNS ,_, SIV3+_NP and_CC 8.2_CD ,_, are_VBP hereafter_RB referred_VBN to_TO as_IN SIV_NP and_CC HIV_NP ,_, respectively_RB ._SENT Both_DT constructs_NNS express_VBP the_DT complete_JJ sets_NNS of_IN structural_JJ and_CC accessory_JJ viral_JJ proteins_NNS with_IN the_DT exception_NN of_IN Env_NP and_CC Vpu_NP (_( in_IN HIV-1_NP )_) and_CC are_VBP devoid_JJ of_IN the_DT packaging_NN sequence_NN ,_, PSI_NP ,_, to_TO impair_VB incorporation_NN of_IN FL_NP viral_JJ genomic_JJ RNA_NP into_IN virion_NN particles_NNS ._SENT The_DT lentivirus-derived_JJ vector_NN genomes_NNS gae-pgk_NN and_CC pRRLsin.PPT.hPGK.GFPpre_NN are_VBP hereafter_RB referred_VBN to_TO as_IN siv_NP and_CC hiv_NP ,_, respectively_RB ._SENT The_DT vesicular_JJ stomatitis_NN virus_NN G_NP (_( VSVg_NP )_) envelope_NN protein_NN that_IN pseudotypes_NNS lentiviral_JJ particles_NNS efficiently_RB and_CC allows_VBZ for_IN broad_JJ cell_NN tropism_NN was_VBD expressed_VBN from_IN the_DT plasmid_NP MD.G_NP ._SENT Virion_NP particle_NN production_NN and_CC purification_NN ._SENT |_SYM LVs_NP were_VBD produced_VBN by_IN calcium_NN phosphate_NN DNA_NN transfection_NN of_IN 293T_JJ cells_NNS and_CC were_VBD pseudotyped_JJ with_IN the_DT VSVg_NP envelope_NN ._SENT Forty-eight_NN hours_NNS after_IN transfection_NN ,_, supernatant_JJ of_IN transfected_JJ cells_NNS was_VBD harvested_VBN and_CC purified_VBN essentially_RB ,_, as_RB described_VBN before_RB ._SENT Briefly_RB ,_, supernatant_JJ was_VBD filtered_VBN (_( pore_NN size_NN ,_, 0.45_CD mum_NN )_) and_CC purified_VBN through_IN a_DT double-step_JJ sucrose_NN cushion_NN (_( 45_CD to_TO 25_CD %_NN [_SYM wt/vol_NN ]_SYM )_) ._SENT After_IN ultracentrifugation_NN for_IN 2_CD h_NN at_IN 25,000_CD rpm_NN in_IN a_DT Beckman_NP centrifuge_NN ,_, the_DT interface_NN between_IN the_DT 45_CD and_CC 25_CD %_NN sucrose_NN was_VBD harvested_VBN ,_, diluted_VBD three_CD times_NNS in_IN phosphate-buffered_JJ saline_NN ,_, and_CC recentrifuged_VBD under_IN the_DT same_JJ conditions_NNS onto_IN a_DT single_JJ 25_CD %_NN sucrose_NN cushion_NN ._SENT At_IN the_DT end_NN of_IN the_DT ultracentrifugation_NN ,_, virions_NNS were_VBD resuspended_VBN in_IN RPMI_NP 1640_CD medium_NN devoid_JJ of_IN serum_NN and_CC supplemented_VBN with_IN 10_CD mM_NP MgCl2_NP and_CC 200_CD muM_NN deoxynucleoside_NN triphosphates_NNS ,_, aliquoted_JJ ,_, and_CC frozen_VBN ._SENT Normalization_NN of_IN virions_NNS contained_VBN in_IN the_DT different_JJ viral_JJ preparations_NNS was_VBD carried_VBN out_RP either_CC by_IN normalization_NN for_IN protein_NN content_NN by_IN using_VBG the_DT exogenous_JJ reverse_JJ transcriptase_NN assay_NN as_RB described_VBD previously_RB or_CC by_IN determining_VBG the_DT infectious_JJ titers_NNS after_IN transduction_NN of_IN HeLa_NP or_CC 293T_JJ cells_NNS ,_, which_WDT are_VBP used_VBN as_IN standard_JJ cells_NNS in_IN our_PP$ laboratory_NN ._SENT Generally_RB ,_, quantifications_NNS determined_VBN by_IN protein_NN content_NN and_CC infectious_JJ titers_NNS agreed_VBD ._SENT Cell_NN transduction_NN with_IN LVs_NP ._SENT |_SYM A_DT total_NN of_IN 105_CD cells_NNS were_VBD used_VBN for_IN transduction_NN with_IN LVs_NP ._SENT Adherent_JJ cells_NNS were_VBD plated_VBN onto_IN 12-well_NP plates_NNS (_( 24-well_JJ plates_NNS for_IN macrophages_NNS )_) the_DT day_NN before_IN transduction_NN ._SENT Nonadherent_JJ cells_NNS were_VBD instead_RB plated_VBN onto_IN 96-well_NP plates_VBZ the_DT same_JJ day_NN as_IN transduction_NN ._SENT Transductions_NNS were_VBD carried_VBN out_RP in_IN the_DT presence_NN of_IN 6_CD mug_NN of_IN polybrene_NN (Sigma)/ml_NN for_IN 2_CD h_NN at_IN 37C_JJ ._SENT Cells_NNS were_VBD then_RB spun_VBN directly_RB in_IN the_DT plate_NN ;_: the_DT medium_NN was_VBD removed_VBN and_CC replaced_VBN with_IN fresh_JJ medium_NN ._SENT Cell_NN transduction_NN was_VBD examined_VBN 3_CD to_TO 4_CD days_NNS posttransduction_NN by_IN flow_NN cytometry_NN by_IN determining_VBG the_DT percentage_NN of_IN cells_NNS expressing_VBG the_DT enhanced_JJ green_JJ fluorescent_JJ protein_NN (_( eGFP_NN )_) reporter_NN gene_NN carried_VBN by_IN the_DT LVs_NP ._SENT When_WRB growth_NN arrested_VBD ,_, cells_NNS were_VBD gamma-irradiated_VBN at_IN 3,000_CD rad_NN ._SENT To_TO distinguish_VB and_CC discard_VB highly_RB contaminated_JJ viral_JJ preparations_NNS ,_, control_NN infections_NNS were_VBD routinely_RB performed_VBN in_IN the_DT presence_NN of_IN nucleoside_NN analogs_NNS zidovudine_NP (_( at_IN 10_CD mug/ml_NN ;_: catalog_NN no_RB ._SENT 3485_LS )_) and_CC 2',3'-dideoxycytidine_JJ (_( at_IN 20_CD mug/ml_NN ;_: catalog_NN no_RB ._SENT 220_LS )_) ,_, both_CC obtained_VBD through_IN the_DT AIDS_NP reagent_NN and_CC reference_NN program_NN ,_, NIH_NP ._SENT These_DT infections_NNS allow_VBP for_IN the_DT distinction_NN between_IN eGFP_NN transgene_NN expression_NN following_VBG lentiviral_JJ transduction_NN and_CC eGFP_NN protein_NN carryover_NN and_CC internalization_NN (_( transduction_NN as_IN opposed_VBN to_TO pseudotransduction_NN )_) ._SENT Western_JJ blot_NN analysis_NN and_CC antibodies_NNS ._SENT |_SYM Cell_NN and_CC virion_NN lysates_NNS were_VBD prepared_VBN and_CC analyzed_VBN by_IN using_VBG standard_JJ procedures_NNS ._SENT A_DT monoclonal_NN anti-CA_NN antibody_NN that_WDT recognized_VBD both_DT SIV_NP and_CC HIV_NP CA_NP (_( catalog_NN no_RB ._SENT 3537_LS ;_: obtained_VBN from_IN the_DT AIDS_NP reagent_NN and_CC reference_NN program_NN ,_, NIH_NP )_) was_VBD used_VBN ;_: the_DT monoclonal_NN anti-VSVg_NN antibody_NN was_VBD clone_NN P5D4_NP (_( Sigma_NP )_) ._SENT Slot_NN blot_NN analysis_NN of_IN viral_JJ genomic_JJ RNA_NP ._SENT |_SYM Slot_NP blot_NN analysis_NN of_IN viral_JJ genomic_JJ RNA_NP was_VBD carried_VBN out_RP essentially_RB as_RB described_VBN before_RB ._SENT Briefly_RB ,_, virions_NNS produced_VBD by_IN calcium_NN phosphate_NN transfection_NN of_IN 293T_JJ cells_NNS were_VBD purified_VBN by_IN ultracentrifugation_NN through_IN sucrose_NN as_RB described_VBD above_IN ,_, normalized_VBN by_IN using_VBG exogenous_JJ reverse_JJ transcriptase_NN activity_NN or_CC infectious_JJ titers_NNS ,_, and_CC transferred_VBN onto_IN a_DT nylon_NN membrane_NN by_IN using_VBG a_DT slot_NN blot_NN apparatus_NN ._SENT The_DT membrane_NN was_VBD incubated_VBN overnight_RB at_IN 42C_JJ in_IN a_DT solution_NN containing_VBG 10_CD %_NN polyethylene_NN glycol_NN ,_, 1.5x_NP SSPE_NP (_( 1x_NP SSPE_NP is_VBZ 0.18_CD M_NP NaCl_NP ,_, 10_CD mM_NP NaH2PO4_NP ,_, and_CC 1_CD mM_NP EDTA_NP [_SYM pH_NN 7.7_CD ]_SYM )_) ,_, 7_CD %_NN sodium_NN dodecyl_NN sulfate_NN (_( SDS_NP )_) ,_, and_CC 100_CD mug_NN of_IN salmon_NN sperm_NN DNA/ml_NP with_IN a_DT 32P-end-labeled_JJ DNA_NN probe_NN that_WDT hybridizes_VBZ to_TO the_DT eGFP_NN gene_NN sequence_NN 5'-GGCCGTTTACGTCGCCGTCCAGC-3_NN '_POS present_NN on_IN both_DT hiv-_NN and_CC siv-derived_JJ vector_NN genomes_NNS ._SENT The_DT membrane_NN was_VBD washed_VBN in_IN 0.1_CD %_NN SDS-0.2x_NP SSC_NP (_( 1x_NP SSC_NP is_VBZ 0.15_CD M_NP NaCl_NP plus_CC 0.015_CD M_NP sodium_NN citrate_NN )_) and_CC exposed_VBN for_IN phosphorimager_NN analysis_NN ._SENT Analysis_NN of_IN reverse_JJ transcriptase_NN intermediates_NNS in_IN transduced_JJ cells_NNS ._SENT |_SYM For_IN PCR_NP analysis_NN ,_, DCs_NP and_CC HeLa_NP cells_NNS were_VBD analyzed_VBN in_IN parallel_NN ._SENT Transduction_NN was_VBD carried_VBN out_RP at_IN multiplicities_NNS of_IN infection_NN (_( MOIs_NP )_) ranging_VBG from_IN 0.5_CD to_TO 2_CD ,_, as_RB described_VBN above_IN ._SENT Cell_NN aliquots_NNS were_VBD harvested_VBN at_IN 2_CD and_CC 24_CD h_NN posttransduction_NN and_CC lysed_VBN in_IN a_DT solution_NN containing_VBG 50_CD mM_NP KCl_NP ,_, 10_CD mM_NP Tris-HCl_NP (_( pH_NN 8.3_CD )_) ,_, 2.5_CD mM_NP MgCl2_NP ,_, 0.5_CD %_NN NP-40_NP ,_, 0.5_CD %_NN Tween-20_NN ,_, and_CC 120_CD mug_NN of_IN proteinase_NN K/ml_NP for_IN 1_CD h_NN at_IN 60C_JJ ._SENT Proteinase_NN K_NN was_VBD inactivated_VBN for_IN 30_CD min_NN at_IN 95C_NN ,_, and_CC lysates_NNS were_VBD used_VBN directly_RB for_IN PCR_NP analysis_NN (_( in_IN fivefold_JJ dilutions_NNS )_) ._SENT PCRs_NNS were_VBD carried_VBN out_RP with_IN 2.5_CD U_NN of_IN Taq_NP DNA_NP polymerase_NN (_( Promega_NP )_) in_IN the_DT presence_NN of_IN a_DT solution_NN containing_VBG 1.5_CD mM_NP MgCl2_NP ,_, 5_CD mM_NP Tris-HCl_NP (_( pH_NN 8.0_CD )_) ,_, 10_CD mM_NP NaCl_NP ,_, 0.01_CD mM_NP EDTA_NP ,_, 0.1_CD mM_NP dithiothreitol_NP (_( DTT_NP )_) ,_, 5_CD %_NN glycerol_NN ,_, 0.1_CD %_NN Triton_NP X-100_NP ,_, 200_CD muM_NN deoxynucleoside_NN triphosphates_NNS ,_, and_CC 10_CD pmol_NN of_IN each_DT primer_NN in_IN a_DT final_JJ volume_NN of_IN 50_CD mul_NN ._SENT Amplifications_NNS were_VBD carried_VBN out_RP by_IN using_VBG 30_CD to_TO 40_CD cycles_NNS as_RB follows_VBZ :_: 92C_NN for_IN 30_CD s_NNS ,_, 55C_NN for_IN 30_CD s_NNS ,_, and_CC 72C_NP for_IN 45_CD s._JJ Primer_NP sequences_NNS were_VBD as_RB follows_VBZ (_( from_IN 5_CD '_'' to_TO 3_CD '_POS ;_: nucleotide_NN numbers_NNS within_IN brackets_NNS refer_VBP to_TO the_DT complete_JJ SIVMAC251_JJ sequence_NN [_SYM accession_NN number_NN ]_SYM )_) :_: minus-strand_NN strong_JJ stop_NN (_( MSSS_NP )_) primers_NNS PE103_NP ,_, AGTCGCTCTGCGGAGAGGCTG_NP (_( nucleotides_NNS [_SYM nt_RB ]_SYM 507_CD to_TO 527_CD )_) ,_, and_CC PE83_NP ,_, TGCTAGGGATTTTCCTGC_NP (_( nt_NN 789_CD to_TO 807_CD )_) ;_: FL_NP product_NN primers_NNS 39_CD ,_, CCGTCGTGGTTGGTTCCTGCCG_NP (_( nt_NN 878_CD to_TO 899_CD )_) ,_, and_CC 40_CD ,_, GCTAGATACCCAGAAGAGTTGGAAG_NP (_( nt_NN 294_CD to_TO 309_CD )_) ;_: 2LTR_JJ primers_NNS PE107_JJ ,_, AGCTGCCATTTTAGAAGTAAGCC_NP (_( nt_NN 664_CD to_TO 686_CD )_) ,_, and_CC PE151_NP ,_, TCTGACAGGCCTGACTTGC_NP (_( nt_NN 318_CD to_TO 336_CD )_) ;_: mitochondrial_JJ DNA_NN (_( as_IN in_IN reference_NN )_) primers_NNS 98_CD ,_, GAATGTCTGCACAGCCACTTTCCAC_NP ,_, and_CC 99_CD ,_, GATCGTGGTGATTTAGAGGGTGAAC_NP ;_: and_CC actinup_NN ,_, CGAGAAGATGACCCAGATC_NP ,_, and_CC actindown_NN ,_, TGCCGCCAGACAGCACTGTG_NP ._SENT Probe_NN sequences_NNS were_VBD ,_, respectively_RB ,_, primer_JJR PE107_JJ ;_: primer_JJR PE107_JJ ;_: primer_NN 40_CD ;_: probe_NN 100_CD ,_, TGGGGTTTGGCAGAGATGT_NP ;_: and_CC actinprobe_NN ,_, GGAGAAGAGCTACGAGCTGC_NP ._SENT The_DT products_NNS obtained_VBN after_IN PCR_NP amplification_NN were_VBD transferred_VBN onto_IN a_DT nylon_NN membrane_NN and_CC hybridized_VBN with_IN the_DT specific_JJ 32P-end-labeled_JJ probe_NN ._SENT The_DT intensity_NN of_IN the_DT signals_NNS obtained_VBN after_IN hybridization_NN was_VBD determined_VBN by_IN phosphorimager_NN analysis_NN ._SENT Subcellular_JJ fractionation_NN ._SENT |_SYM Cells_NP were_VBD transduced_VBN and_CC analyzed_VBN 24_CD h_NN posttransduction_NN by_IN following_VBG a_DT procedure_NN described_VBD previously_RB ,_, with_IN minor_JJ modifications_NNS ._SENT Briefly_RB ,_, cells_NNS were_VBD washed_VBN in_IN cold_JJ phosphate-buffered_JJ saline_NN and_CC then_RB resuspended_JJ in_IN a_DT solution_NN containing_VBG 10_CD mM_NP Tris-HCl_NP (_( pH_NN 8.0_CD )_) ,_, 1.5_CD mM_NP MgCl2_NP ,_, 10_CD mM_NP KCl_NP ,_, and_CC 2_CD mM_NP DTT_NP ._SENT Cells_NNS were_VBD vortexed_VBN and_CC incubated_VBN for_IN 1_CD min_NN on_IN ice_NN ._SENT Cells_NNS were_VBD then_RB spun_VBN at_IN 5,500_CD rpm_NN for_IN 5_CD min_NN ,_, and_CC the_DT supernatant_JJ was_VBD transferred_VBN to_TO a_DT new_JJ tube_NN (_( fraction_NN 1_CD ,_, cytoplasmic_JJ fraction_NN )_) ._SENT The_DT fraction_NN was_VBD clarified_VBN by_IN centrifugation_NN at_IN 14,000_CD rpm_NN in_IN a_DT Hedaeus_NP centrifuge_NN for_IN 10_CD min_NN ._SENT The_DT nuclear_JJ fraction_NN was_VBD washed_VBN twice_RB in_IN the_DT buffer_NN mentioned_VBN above_IN ,_, and_CC the_DT supernatant_JJ was_VBD pooled_VBN and_CC clarified_VBN as_IN described_VBN above_IN (_( fraction_NN 2_CD ,_, control_NN for_IN integrity_NN of_IN the_DT nuclear_JJ fraction_NN )_) ._SENT The_DT pellet_NN containing_VBG the_DT nuclei_NNS was_VBD lysed_VBN and_CC vortexed_VBN in_IN a_DT solution_NN containing_VBG 10_CD mM_NP Tris-HCl_NP (_( pH_NN 7.4_CD )_) ,_, 5_CD mM_NP MgCl2_NP ,_, 160_CD mM_NP KCl_NP ,_, 1_CD mM_NP DTT_NP ,_, 0.6_CD %_NN SDS_NP ,_, and_CC glass_NN beads_NNS (_( fraction_NN 3_CD ,_, nuclear_JJ fraction_NN )_) ._SENT All_DT fractions_NNS were_VBD adjusted_VBN for_IN identical_JJ salt_NN concentrations_NNS and_CC incubated_VBN at_IN 60C_JJ for_IN 1_CD h_NN after_IN addition_NN of_IN 120_CD mug_NN of_IN proteinase_NN K/ml_NP ._SENT Lysates_NNS were_VBD treated_VBN for_IN PCR_NP analysis_NN ,_, as_RB described_VBN above_IN ._SENT Cell-specific_JJ infectivity_NN defect_NN of_IN an_DT HIV-1_NP LV_NP packaging_VBG an_DT siv-derived_JJ genome_NN ._SENT |_SYM To_TO develop_VB heterologous_JJ LVs_NP with_IN HIV-1_NP packaging_VBG an_DT siv-derived_JJ genome_NN ,_, we_PP used_VBD comparable_JJ ,_, although_IN not_RB identical_JJ ,_, versions_NNS of_IN HIV-1_NP and_CC SIVMAC251_NP LVs_NP ._SENT The_DT HIV-1_NP and_CC the_DT SIVMAC251_JJ packaging_NN constructs_NNS ,_, referred_VBD to_TO as_IN HIV_NP and_CC SIV_NP ,_, respectively_RB ,_, are_VBP devoid_JJ of_IN the_DT packaging_NN sequences_NNS PSI_NP and_CC env_NP ,_, code_NN for_IN Gag-Pro-Pol_NP ,_, and_CC express_VB the_DT complete_JJ set_NN of_IN accessory_JJ viral_JJ genes_NNS ._SENT Both_DT lentivirus-derived_JJ vector_NN genomes_NNS ,_, referred_VBD to_TO as_IN hiv_NP and_CC siv_NP ,_, bear_VBP an_DT eGFP_NN expression_NN cassette_NN ._SENT Besides_IN this_DT ,_, they_PP carry_VBP the_DT cis_NN sequences_NNS required_VBN for_IN transcription_NN ,_, splicing_VBG (_( the_DT major_JJ viral_JJ splice_NN donor_NN and_CC acceptor_NN sites_NNS )_) ,_, nuclear_JJ export_NN (_( the_DT Rev-responsive_JJ element_NN [_SYM RRE_NP ]_SYM )_) ,_, packaging_NN (_( PSI_NP )_) ,_, and_CC reverse_JJ transcription_NN (_( primer_JJR binding_JJ site_NN [_SYM PBS_NP ]_SYM and_CC 3_CD '_POS polypurine_JJ tract_NN [_SYM PPT_NN ]_SYM )_) of_IN the_DT vector_NN genome_NN ._SENT They_PP also_RB bear_VBP a_DT central_JJ polypurine_NN tract-central_JJ termination_NN sequence_NN (_( cPPT-CTS_NNS )_) ._SENT The_DT cPPT_NN increases_VBZ the_DT efficacy_NN of_IN cell_NN transduction_NN by_IN LVs_NP ,_, although_IN the_DT function_NN of_IN this_DT sequence_NN is_VBZ actually_RB debated_VBN ._SENT The_DT woodchuck_NN hepatitis_NN virus_NN posttranscriptional_JJ regulatory_JJ element_NN (_( Wpre_NP )_) that_WDT increases_VBZ transgene_NN expression_NN by_IN stabilizing_VBG mRNAs_NNS in_IN cis_NNS is_VBZ present_JJ on_IN hiv_NP but_CC not_RB on_IN siv_NP ._SENT The_DT presence_NN of_IN this_DT element_NN increases_VBZ transgene_JJ expression_NN in_IN HIV-1_JJ vectors_NNS ,_, but_CC for_IN unknown_JJ reasons_NNS it_PP is_VBZ detrimental_JJ during_IN the_DT transduction_NN of_IN certain_JJ cell_NN types_NNS by_IN SIV_NP LVs_NP ._SENT As_IN such_JJ ,_, Wpre_NP was_VBD not_RB present_JJ in_IN our_PP$ siv-derived_JJ vector_NN genome_NN ._SENT Homologous_JJ HIV-hiv_NP and_CC SIV-siv_NP LVs_NP were_VBD produced_VBN along_RP with_IN the_DT heterologous_JJ HIV-siv_NP vector_NN by_IN calcium_NN phosphate_NN transfection_NN of_IN 293T_JJ cells_NNS with_IN the_DT DNAs_NP shown_VBN in_IN Fig._NN ._SENT All_DT LVs_NP were_VBD pseudotyped_JJ with_IN the_DT VSVg_NP envelope_NN to_TO allow_VB for_IN broad_JJ cell_NN tropism_NN of_IN viral_JJ particles_NNS ._SENT As_IN a_DT first_JJ step_NN towards_IN the_DT characterization_NN of_IN heterologous_JJ LVs_NP ,_, virions_NNS were_VBD normalized_VBN by_IN exogenous_JJ reverse_JJ transcriptase_NN activity_NN and_CC their_PP$ infectious_JJ titers_NNS were_VBD determined_VBN upon_IN transduction_NN of_IN HeLa_NP cells_NNS ._SENT While_IN all_DT vectors_NNS had_VBD similar_JJ levels_NNS of_IN infectivity_NN ,_, SIV-hiv_NP LV_NP titers_NNS were_VBD drastically_RB reduced_VBN ._SENT Given_VBN the_DT data_NNS described_VBN in_IN the_DT literature_NN ,_, this_DT defect_NN is_VBZ not_RB surprising_JJ and_CC it_PP is_VBZ most_RBS probably_RB caused_VBN by_IN the_DT inability_NN of_IN SIV_NP virions_NNS to_TO cross_VB package_NN an_DT hiv_NN genome_NN ._SENT For_IN this_DT reason_NN ,_, SIV-hiv_NP LVs_NP were_VBD not_RB used_VBN any_DT further_RBR in_IN subsequent_JJ experiments_NNS ._SENT To_TO normalize_VB the_DT different_JJ viral_JJ preparations_NNS ,_, we_PP routinely_RB determined_VBD their_PP$ infectious_JJ titers_NNS in_IN 293T_NP or_CC HeLa_NP cells_NNS ,_, highly_RB permissive_JJ to_TO both_DT SIV_NP and_CC HIV_NP transduction_NN ._SENT This_DT method_NN very_RB closely_RB ,_, albeit_IN not_RB identically_RB ,_, mirrored_VBD normalization_NN by_IN protein_NN content_NN ,_, as_RB determined_VBN by_IN exogenous_JJ reverse_JJ transcriptase_NN activity_NN and_CC Western_JJ blotting_VBG (_( data_NNS not_RB shown_VBN )_) ._SENT To_TO exclude_VB the_DT possibility_NN of_IN pseudotransduction_NN ,_, i.e._FW ,_, the_DT presence_NN of_IN intracellular_JJ eGFP_NN signal_NN in_IN target_NN cells_NNS due_JJ to_TO protein_NN carryover_NN or_CC phagocytosis_NN rather_RB than_IN viral_JJ transduction_NN ,_, control_NN test_NN infections_NNS were_VBD routinely_RB performed_VBN in_IN the_DT presence_NN of_IN reverse_JJ transcriptase_NN inhibitors_NNS ._SENT Normalized_VBN amounts_NNS of_IN virions_NNS were_VBD used_VBN for_IN parallel_JJ transduction_NN of_IN HeLa_NP cells_NNS ,_, as_IN a_DT control_NN ,_, and_CC DCs_NP ,_, the_DT latter_NN being_VBG an_DT important_JJ cell_NN target_NN in_IN gene_NN therapy_NN and_CC in_IN HIV_NP pathogenesis_NN ._SENT HeLa_NN cells_NNS and_CC DCs_NP were_VBD transduced_VBN with_IN the_DT same_JJ MOIs_NN in_IN logarithmic_JJ dilutions_NNS ._SENT As_IN expected_VBN ,_, HeLa_NP cells_NNS were_VBD equally_RB well_RB transduced_JJ by_IN all_DT vectors_NNS ,_, irrespective_RB of_IN their_PP$ cycling_NN status_NN (_( data_NNS not_RB shown_VBN )_) ._SENT DCs_NNS were_VBD more_RBR refractory_JJ to_TO transduction_NN with_IN LVs_NP than_IN were_VBD HeLa_NP cells_NNS ,_, as_RB indicated_VBN by_IN the_DT lower_JJR percentages_NNS of_IN transduced_JJ cells_NNS for_IN the_DT same_JJ MOIs_NP ._SENT However_RB ,_, both_DT homologous_JJ SIV_NP and_CC HIV_NP vectors_NNS transduced_VBD DCs_NP well_RB and_CC routinely_RB ;_: transduction_NN efficiencies_NNS of_IN around_RB 60_CD to_TO 90_CD %_NN were_VBD attained_VBN with_IN an_DT MOI_NP of_IN 10_CD ._SENT MOIs_NNS higher_JJR than_IN 10_CD were_VBD avoided_VBN ,_, since_IN we_PP noticed_VBD a_DT negative_JJ impact_NN on_IN DC_NP viability_NN and_CC morphology_NN under_IN these_DT conditions_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT homologous_JJ SIV_NP vector_NN was_VBD between_IN five-_NN and_CC 10-fold_NN less_CC infectious_JJ than_IN its_PP$ HIV-1_JJ counterpart_NN in_IN human_JJ DCs_NP ,_, a_DT defect_NN present_NN at_IN low_JJ but_CC not_RB at_IN high_JJ MOIs_NP ._SENT This_DT observation_NN is_VBZ reminiscent_JJ of_IN the_DT Fv1-like_JJ cell_NN restriction_NN recently_RB described_VBD for_IN primate_NN lentiviruses_NNS and_CC may_MD explain_VB why_WRB HIV-1_JJ vectors_NNS transduce_VBP human_JJ cells_NNS better_RBR than_IN their_PP$ SIV_NP counterparts_NNS (_( see_VB below_IN )_) ._SENT In_IN contrast_NN to_TO homologous_JJ SIV_NP and_CC HIV_NP LVs_NP ,_, transduction_NN of_IN DCs_NP with_IN the_DT HIV-siv_NP vector_NN was_VBD severely_RB impaired_JJ (_( at_IN least_JJS 100-fold_NN )_) ._SENT This_DT impairment_NN cannot_MD be_VB explained_VBN by_IN loss_NN of_IN infectivity_NN of_IN heterologous_JJ HIV-siv_NP LVs_NP ,_, as_IN these_DT do_VBP transduce_VB HeLa_NP cells_NNS efficiently_RB ._SENT As_IN certain_JJ postentry_NN blocks_NNS may_MD be_VB determined_VBN by_IN the_DT entry_NN pathway_NN used_VBN by_IN the_DT virus_NN ,_, LVs_NP were_VBD pseudotyped_JJ with_IN an_DT HIV-1_NP R5_NP envelope_NN protein_NN (_( JR-FL_NP )_) and_CC used_VBN for_IN DC_NP transduction_NN ._SENT Similar_JJ to_TO what_WP was_VBD observed_VBN with_IN VSVg-pseudotyped_NP LVs_NP ,_, heterologous_JJ HIV-siv_NP LVs_NP were_VBD unable_JJ to_TO transduce_VB DCs_NP ._SENT These_DT results_NNS show_VBP a_DT drastic_JJ infectivity_NN defect_NN of_IN HIV-siv_NP LVs_NP in_IN DCs_NP that_WDT is_VBZ independent_JJ from_IN the_DT viral_JJ entry_NN pathway_NN used_VBD ._SENT The_DT infectivity_NN defect_NN of_IN the_DT HIV-siv_NP vector_NN is_VBZ specific_JJ for_IN DCs_NP and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, macrophages_NNS ._SENT |_SYM To_TO determine_VB whether_IN the_DT infectivity_NN defect_NN of_IN HIV-siv_NP virions_NNS was_VBD specific_JJ for_IN DCs_NP ,_, different_JJ human_JJ cell_NN lines_NNS and_CC primary_JJ blood_NN cells_NNS were_VBD analyzed_VBN for_IN their_PP$ susceptibility_NN to_TO transduction_NN with_IN LVs_NP ._SENT Virions_NNS were_VBD purified_VBN as_IN described_VBN above_IN and_CC used_VBN in_IN the_DT transduction_NN of_IN the_DT human_JJ monocytic_JJ cell_NN lines_NNS U937_JJ and_CC HL60_JJ and_CC primary_JJ macrophages_NNS at_IN MOIs_NP of_IN 5_CD ,_, 0.5_CD ,_, and_CC 0.05_CD ._SENT Similarly_RB ,_, identical_JJ amounts_NNS of_IN virions_NNS were_VBD used_VBN to_TO transduce_VB the_DT lymphocytoid_JJ Jurkat_NP cell_NN line_NN and_CC primary_JJ PBLs_NNS that_WDT had_VBD been_VBN activated_VBN with_IN PHA-IL-2_NP or_CC IL-7_JJ for_IN 24_CD h_NN ._SENT As_IN transduction_NN of_IN unstimulated_JJ PBLs_NNS did_VBD not_RB yield_VB appreciable_JJ transduction_NN rates_NNS ,_, it_PP was_VBD not_RB examined_VBN further_JJR (_( data_NNS not_RB shown_VBN )_) ._SENT All_PDT the_DT cell_NN lines_NNS tested_VBN in_IN this_DT study_NN were_VBD transduced_VBN more_RBR efficiently_RB than_IN primary_JJ cells_NNS ,_, regardless_RB of_IN the_DT cycling_NN statuses_NNS of_IN the_DT cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Generally_RB ,_, the_DT homologous_JJ HIV-hiv_NP vector_NN had_VBD an_DT advantage_NN compared_VBN with_IN SIV_NP in_IN the_DT transduction_NN of_IN all_PDT the_DT human_JJ cells_NNS tested_VBN in_IN this_DT study_NN ._SENT The_DT magnitude_NN of_IN this_DT advantage_NN varied_VBN among_IN the_DT cell_NN lines_NNS (_( from_IN five-_NN to_TO eightfold_JJ )_) and_CC was_VBD more_RBR marked_VBN at_IN low_JJ rather_RB than_IN high_JJ MOIs_NP ,_, at_IN which_WDT SIV_NP and_CC HIV_NP transduction_NN rates_NNS were_VBD close_JJ to_TO equal_VB ._SENT With_IN primary_JJ lymphocytes_NNS instead_RB ,_, HIV_NP maintained_VBD its_PP$ advantage_NN over_IN SIV_NP at_IN all_DT MOIs_NP ._SENT Contrary_JJ to_TO what_WP was_VBD observed_VBN with_IN DCs_NP ,_, heterologous_JJ HIV-siv_NP virion_NN particles_NNS were_VBD able_JJ to_TO efficiently_RB transduce_VB all_PDT the_DT other_JJ cells_NNS tested_VBN in_IN this_DT study_NN (_( with_IN the_DT exception_NN of_IN primary_JJ macrophages_NNS ;_: see_VB below_IN )_) ._SENT The_DT infectivity_NN of_IN HIV-siv_NP virions_NNS neared_VBD that_IN of_IN homologous_JJ HIV-hiv_NP particles_NNS and_CC was_VBD consistently_RB higher_JJR than_IN that_DT of_IN SIV_NP ._SENT The_DT only_JJ difference_NN among_IN homologous_JJ and_CC heterologous_JJ HIV_NP vectors_NNS was_VBD a_DT slightly_RB lower_JJR infectivity_NN of_IN the_DT latter_JJ (_( one-_JJ to_TO threefold_RB )_) ,_, probably_RB due_JJ to_TO intrinsic_JJ differences_NNS between_IN the_DT hiv_NP and_CC siv_NP genomic_JJ constructs_NNS ._SENT With_IN primary_JJ macrophages_NNS however_RB ,_, the_DT difference_NN between_IN homologous_JJ and_CC heterologous_JJ HIV_NP vectors_NNS reached_VBD 10-fold_NN ._SENT This_DT defect_NN was_VBD not_RB as_RB marked_JJ as_IN it_PP was_VBD in_IN DCs_NP but_CC was_VBD nevertheless_RB readily_RB distinguishable_JJ ._SENT Overall_RB ,_, these_DT results_NNS show_VBP that_IN the_DT infectivity_NN defect_NN of_IN HIV-siv_NP virion_NN particles_NNS is_VBZ restricted_VBN to_TO DCs_NP and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, macrophages_NNS ,_, suggesting_VBG a_DT cell-specific_JJ infectivity_NN defect_NN ._SENT Characterization_NN of_IN HIV-siv_NP virion_NN particles_NNS ._SENT |_SYM The_DT fact_NN that_IN HIV-siv_NP virion_NN particles_NNS efficiently_RB transduced_VBD different_JJ cell_NN types_NNS argues_VBZ against_IN an_DT intrinsic_JJ defect_NN of_IN such_JJ particles_NNS ._SENT However_RB ,_, to_TO exclude_VB completely_RB this_DT possibility_NN ,_, homologous_JJ HIV_NP and_CC SIV_NP virions_NNS were_VBD compared_VBN with_IN HIV-siv_NP virion_NN particles_NNS with_IN respect_NN to_TO their_PP$ protein_NN profiles_NNS and_CC genomic_JJ RNA_NP contents_NNS ._SENT Normalized_VBN amounts_NNS of_IN virion_NN particles_NNS were_VBD analyzed_VBN by_IN Western_NP blotting_VBG by_IN using_VBG an_DT anti-VSVg_NN and_CC an_DT anti-CA_NP antibody_NN that_WDT recognizes_VBZ both_DT SIV_NP and_CC HIV-1_NP CAs_NP ._SENT As_IN expected_VBN ,_, virions_NNS contained_VBD similar_JJ amounts_NNS of_IN Gag_NP and_CC VSVg_NP proteins_NNS regardless_RB of_IN the_DT vector_NN genome_NN incorporated_VBN (_( Fig._NN ,_, lanes_NNS 2_CD and_CC 3_CD and_CC 5_CD and_CC 6_CD )_) ._SENT Gag_NN processing_NN by_IN the_DT viral_JJ protease_NN was_VBD also_RB unmodified_JJ in_IN HIV_NP particles_NNS ,_, regardless_RB of_IN the_DT vector_NN genome_NN packaged_VBN ._SENT Next_RB ,_, the_DT amount_NN of_IN viral_JJ genomic_JJ RNA_NP incorporated_VBN into_IN the_DT particles_NNS was_VBD determined_VBN by_IN slot_NN blot_NN analysis_NN by_IN using_VBG procedures_NNS described_VBD previously_RB ._SENT RNA_NP derived_VBD from_IN MOI-normalized_JJ amounts_NNS of_IN virion_NN particles_NNS was_VBD transferred_VBN onto_IN a_DT nylon_NN membrane_NN by_IN using_VBG a_DT slot_NN blot_NN apparatus_NN and_CC hybridized_VBN with_IN a_DT 32P-end-labeled_JJ antisense_NN probe_NN specific_JJ for_IN the_DT common_JJ eGFP_NN gene_NN sequence_NN ._SENT As_IN controls_NNS for_IN plasmid_NP DNA_NP carryover_NN ,_, viral_JJ RNA_NP preparations_NNS were_VBD treated_VBN with_IN RNase_NP A._NP Densitometry_NP analysis_NN revealed_VBD no_DT major_JJ differences_NNS among_IN the_DT levels_NNS of_IN hiv-_NN and_CC siv-derived_JJ vector_NN genomes_NNS incorporated_VBN into_IN HIV_NP virion_NN particles_NNS ._SENT Taken_VBN together_RB ,_, our_PP$ results_NNS indicate_VBP that_IN there_EX is_VBZ no_DT major_JJ structural_JJ difference_NN among_IN homologous_JJ and_CC heterologous_JJ HIV-1_JJ virion_NN particles_NNS ._SENT Characterization_NN of_IN the_DT early_JJ steps_NNS of_IN transduction_NN with_IN HIV-siv_NP LVs_NP by_IN PCR_NP ._SENT |_SYM As_IN the_DT transduction_NN defect_NN of_IN HIV-siv_NP LVs_NP was_VBD more_RBR dramatic_JJ in_IN DCs_NP ,_, we_PP decided_VBD to_TO focus_VB our_PP$ efforts_NNS on_IN these_DT cells_NNS ._SENT To_TO precisely_RB characterize_VB this_DT defect_NN ,_, accumulation_NN of_IN reverse_JJ transcriptase_NN intermediates_NNS was_VBD determined_VBN by_IN semiquantitative_JJ PCR_NP after_IN cell_NN transduction_NN ._SENT To_TO this_DT end_NN ,_, the_DT homologous_JJ SIV-siv_NP vector_NN and_CC the_DT HIV-siv_NP vector_NN were_VBD compared_VBN side_NN by_IN side_NN ._SENT As_IN the_DT two_CD vectors_NNS contain_VBP the_DT same_JJ genome_NN ,_, PCR_NP analysis_NN is_VBZ performed_VBN by_IN using_VBG the_DT same_JJ primers_NNS and_CC the_DT results_NNS obtained_VBN for_IN the_DT two_CD vectors_NNS can_MD be_VB directly_RB compared_VBN ._SENT HeLa_NN cells_NNS and_CC DCs_NP were_VBD transduced_VBN in_IN parallel_NN at_IN MOIs_NP between_IN 0.5_CD and_CC 2_CD in_IN different_JJ experiments_NNS ,_, i.e._FW ,_, at_IN MOIs_NP at_IN which_WDT differences_NNS between_IN HIV_NP and_CC SIV_NP vectors_NNS were_VBD minor_JJ in_IN DCs_NP ._SENT Cell_NN aliquots_NNS were_VBD harvested_VBN at_IN 2_CD and_CC 24_CD h_NN posttransduction_NN and_CC lysed_VBN ,_, and_CC intermediates_NNS representing_VBG the_DT MSSS_NP ,_, the_DT FL_NP ,_, and_CC 2LTR_JJ circles_NNS were_VBD analyzed_VBN by_IN PCR_NP by_IN using_VBG primers_NNS designed_VBN to_TO distinguish_VB each_DT of_IN these_DT forms_NNS ._SENT Cell_NN lysates_NNS were_VBD amplified_VBN in_IN fivefold_JJ dilutions_NNS ,_, and_CC PCR_NP was_VBD performed_VBN in_IN linear_JJ conditions_NNS for_IN semiquantitative_JJ analysis_NN ._SENT The_DT products_NNS obtained_VBN after_IN PCR_NP were_VBD transferred_VBN onto_IN a_DT nylon_NN membrane_NN and_CC hybridized_VBD to_TO a_DT 32P-labeled_JJ internal_JJ probe_NN specific_JJ for_IN each_DT amplified_VBN product_NN ._SENT Consistent_JJ with_IN the_DT similar_JJ infectivities_NNS of_IN SIV-siv_NP and_CC HIV-siv_NP virion_NN particles_NNS ,_, accumulation_NN of_IN MSSS_NP ,_, FL_NP ,_, and_CC 2LTR_JJ circle_NN products_NNS was_VBD equivalent_JJ following_VBG transduction_NN of_IN HeLa_NP cells_NNS ._SENT In_IN DCs_NP ,_, the_DT amounts_NNS of_IN MSSS_NP were_VBD also_RB equivalent_JJ following_VBG transduction_NN with_IN the_DT SIV-siv_NP and_CC HIV-siv_NP vectors_NNS ._SENT FL_NP products_NNS accumulated_VBN normally_RB at_IN 2_CD h_NN ,_, but_CC levels_NNS of_IN these_DT products_NNS were_VBD six-_NN to_TO eightfold_RB lower_JJR at_IN 24_CD h_NN posttransduction_NN with_IN HIV-siv_NP than_IN they_PP were_VBD with_IN SIV-siv_NP ._SENT FL_NP products_NNS were_VBD ,_, however_RB ,_, readily_RB obtained_VBN after_IN transduction_NN of_IN DCs_NP with_IN HIV-siv_NP ._SENT In_IN contrast_NN ,_, accumulation_NN of_IN 2LTR_JJ circles_NNS was_VBD drastically_RB reduced_VBN in_IN DCs_NP transduced_VBD with_IN the_DT heterologous_JJ HIV-siv_NP vector_NN (_( at_IN least_JJS 100-fold_NN compared_VBN to_TO that_DT in_IN DCs_NP transduced_VBD with_IN SIV_NP )_) ._SENT Our_PP$ results_NNS indicate_VBP that_IN HIV-siv_NP virion_NN particles_NNS display_VBP a_DT slight_JJ defect_NN in_IN FL_NP proviral_JJ DNA_NN accumulation_NN and_CC a_DT major_JJ defect_NN in_IN the_DT formation_NN of_IN 2LTR_JJ circles_NNS specifically_RB in_IN DCs_NP ._SENT A_DT defect_NN in_IN 2LTR_JJ circle_NN formation_NN may_MD be_VB explained_VBN by_IN several_JJ possibilities_NNS :_: instability_NN of_IN proviral_JJ DNA_NN ,_, impairment_NN of_IN nuclear_JJ entry_NN ,_, or_CC block_VB at_IN a_DT post-nuclear_JJ migration_NN step_NN ._SENT Proviral_NP DNA_NP of_IN HIV-siv_NP LVs_NP is_VBZ associated_VBN with_IN the_DT nucleus_NN following_VBG subcellular_JJ fractionation_NN of_IN transduced_JJ DCs_NP ._SENT |_SYM To_TO begin_VB to_TO distinguish_VB among_IN the_DT hypotheses_NNS mentioned_VBN above_IN ,_, PCR_NP analysis_NN was_VBD performed_VBN with_IN cytoplasmic_JJ and_CC nuclear_JJ cell_NN fractions_NNS obtained_VBD 24_CD h_NN posttransduction_NN of_IN DCs_NP ._SENT Nuclear_JJ and_CC cytoplasmic_JJ extracts_VBZ were_VBD obtained_VBN according_VBG to_TO procedures_NNS previously_RB established_VBN ,_, and_CC the_DT presence_NN of_IN FL_NP proviral_JJ DNA_NN was_VBD determined_VBN by_IN limiting-dilution_NN PCR_NP ,_, as_RB described_VBN above_IN ._SENT Amplification_NN of_IN actin_NN DNA_NN was_VBD used_VBN as_IN a_DT control_NN for_IN the_DT fractionation_NN procedure_NN and_CC nuclei_NNS integrity_NN ._SENT As_IN expected_VBN ,_, actin_NN DNA_NN was_VBD amplified_VBN essentially_RB from_IN the_DT sole_JJ nuclear_JJ fraction_NN ,_, and_CC only_RB trace_VB amounts_NNS could_MD be_VB found_VBN in_IN the_DT cytoplasmic_JJ and_CC nuclear_JJ wash_NN fractions_NNS ,_, probably_RB as_IN a_DT result_NN of_IN mechanical_JJ breakage_NN of_IN a_DT small_JJ proportion_NN of_IN nuclei_NNS ._SENT When_WRB FL_NP proviral_JJ DNA_NN was_VBD examined_VBN ,_, the_DT amount_NN was_VBD six-_NN to_TO eightfold_RB lower_JJR following_VBG transduction_NN with_IN HIV-siv_NP than_IN that_DT following_VBG transduction_NN with_IN the_DT SIV-siv_NP vector_NN (_( as_RB also_RB shown_VBN in_IN Fig._NN )_) ,_, but_CC in_IN both_DT cases_NNS ,_, nearly_RB all_RB of_IN the_DT FL_NP proviral_JJ DNA_NN was_VBD associated_VBN with_IN the_DT nucleus_NN ._SENT These_DT results_NNS suggest_VBP that_IN the_DT preintegration_NN complex_NN (_( PIC_JJ )_) of_IN the_DT heterologous_JJ HIV-siv_NP vector_NN is_VBZ able_JJ to_TO access_VB the_DT nucleus_NN ,_, although_IN it_PP remains_VBZ formally_RB possible_JJ that_IN proviral_JJ DNA_NN might_MD be_VB tightly_RB tethered_VBN outside_IN the_DT nuclear_JJ membrane_NN rather_RB than_IN inside_IN it_PP ._SENT In_IN addition_NN to_TO its_PP$ purpose_NN with_IN regard_NN to_TO gene_NN therapy_NN ,_, one_CD objective_NN of_IN this_DT study_NN was_VBD to_TO determine_VB whether_IN functions_NNS specified_VBN by_IN cis_NN elements_NNS and_CC trans-acting_VBG factors_NNS of_IN closely_RB related_VBN lentiviruses_NNS were_VBD conserved_VBN during_IN the_DT transduction_NN of_IN different_JJ human_JJ cell_NN types_NNS ._SENT The_DT data_NNS collected_VBD here_RB confirm_VB earlier_JJR findings_NNS ,_, obtained_VBN by_IN using_VBG heterologous_JJ LVs_NP on_IN chemically_RB arrested_VBN cells_NNS and_CC primary_JJ human_JJ macrophages_NNS ,_, that_IN this_DT is_VBZ the_DT case_NN but_CC add_VB the_DT notion_NN that_IN the_DT extent_NN of_IN function_NN conservation_NN may_MD be_VB influenced_VBN on_IN a_DT cell-specific_JJ basis_NN ._SENT Comparison_NN of_IN HIV-1_NP and_CC SIVMAC251_NP LVs_NP in_IN the_DT transduction_NN of_IN human_JJ cells_NNS ._SENT |_SYM Although_IN the_DT data_NNS presented_VBD here_RB are_VBP not_RB meant_VBN to_TO constitute_VB an_DT exhaustive_JJ comparative_JJ study_NN of_IN HIV-1_NP and_CC SIVMAC251_NP vectors_NNS ,_, they_PP provide_VBP some_DT points_NNS of_IN interest_NN towards_IN this_DT end_NN ._SENT Generally_RB ,_, HIV-1_NP LVs_NP (_( both_CC heterologous_JJ and_CC homologous_JJ )_) have_VBP an_DT advantage_NN over_IN SIV_NP LVs_NP in_IN the_DT transduction_NN of_IN all_PDT the_DT human_JJ cells_NNS tested_VBN in_IN this_DT study_NN ,_, and_CC reciprocally_RB ,_, SIV_NP LVs_NP seem_VBP more_RBR infectious_JJ in_IN simian_JJ cells_NNS (_( Vero_NP cells_NNS )_) (_( data_NNS not_RB shown_VBN )_) ._SENT However_RB ,_, with_IN the_DT exception_NN of_IN lymphocytes_NNS ,_, the_DT difference_NN in_IN transduction_NN efficiencies_NNS between_IN HIV_NP and_CC SIV_NP lowers_VBZ with_IN increasing_VBG MOIs_NP ._SENT This_DT observation_NN may_MD reflect_VB general_JJ adaptation_NN of_IN these_DT lentiviruses_NNS for_IN replication_NN in_IN their_PP$ natural_JJ host_NN and_CC their_PP$ ability_NN to_TO overcome_VB restrictions_NNS such_JJ as_IN the_DT one_CD specified_VBN by_IN the_DT resistance_NN factor_NN 1_CD (_( Ref1_NP )_) and_CC the_DT lentiviral_JJ resistance_NN gene_NN (_( Lv-1_NP )_) in_IN primate_NN cells_NNS that_WDT target_VBP incoming_JJ retroviral_JJ capsid_NN proteins_NNS at_IN different_JJ points_NNS postentry_NN ._SENT Although_IN this_DT may_MD partly_RB explain_VB the_DT relative_JJ transduction_NN efficiencies_NNS of_IN SIV_NP and_CC HIV_NP LVs_NP in_IN human_JJ cells_NNS ,_, we_PP ignore_VBP at_IN present_NN the_DT question_NN of_IN whether_IN the_DT phenomenon_NN observed_VBD in_IN this_DT study_NN is_VBZ specified_VBN through_IN similar_JJ mechanisms_NNS ._SENT At_IN any_DT rate_NN ,_, an_DT Lv-1-like_JJ restriction_NN cannot_MD explain_VB the_DT difference_NN between_IN homologous_JJ and_CC heterologous_JJ HIV-1_NP LVs_NP in_IN DCs_NP ,_, as_IN they_PP share_VBP identical_JJ capsids_NNS and_CC should_MD thus_RB be_VB subjected_VBN to_TO the_DT same_JJ restrictions_NNS ._SENT Cell-dependent_JJ transduction_NN defect_NN of_IN HIV-siv_NP LVs_NP ._SENT |_SYM We_PP have_VBP determined_VBN that_IN the_DT transduction_NN defect_NN of_IN HIV-siv_NP LVs_NP observed_VBD in_IN DCs_NP is_VBZ independent_JJ from_IN several_JJ parameters_NNS :_: the_DT viral_JJ entry_NN pathway_NN ,_, as_IN similar_JJ results_NNS were_VBD obtained_VBN whether_IN LVs_NP were_VBD pseudotyped_JJ with_IN VSVg_NP or_CC HIV-1_NP R5_NP (_( JR-FL_NP )_) envelope_NN proteins_NNS ;_: the_DT presence_NN or_CC absence_NN of_IN viral_JJ accessory_JJ proteins_NNS of_IN HIV-1_NP ;_: the_DT specific_JJ transgene_NN expression_NN cassette_NN ;_: the_DT Wpre_NP element_NN ;_: the_DT degree_NN of_IN differentiation_NN of_IN DCs_NP ;_: and_CC the_DT blood_NN donor_NN (_( data_NNS not_RB shown_VBN )_) ._SENT In_IN addition_NN ,_, the_DT HIV-siv_NP transduction_NN defect_NN was_VBD not_RB rescued_VBN by_IN treatment_NN of_IN DCs_NP with_IN As2O3_NP ,_, a_DT drug_NN that_WDT enhances_VBZ retroviral_JJ transduction_NN efficiency_NN by_IN stimulating_VBG reverse_JJ transcription_NN (_( ,_, ;_: data_NNS not_RB shown_VBN )_) ._SENT One_CD possible_JJ explanation_NN for_IN the_DT transduction_NN defect_NN of_IN HIV-siv_NP LVs_NP may_MD be_VB their_PP$ inability_NN to_TO transduce_VB nondividing_JJ cells_NNS ._SENT We_PP believe_VBP this_DT explanation_NN unlikely_JJ for_IN several_JJ reasons_NNS ._SENT HIV-siv_NP vectors_NNS are_VBP f_NN 